钙离子依赖型凝集素样受体2 (CLEC-2)研究进展

 钙离子依赖型凝集素样受体2(calcium dependent lectin like receptor 2,CLEC-2)是近年发现的血小板表面受体,相对分子质量(Mr)约32 000,是一种Ⅱ型跨膜受体。蛇毒蛋白Rhodocytin和唾液酸样糖蛋白Podoplanin是目前被分别鉴定出的CLEC-2的外源性和内源性配体。配体与受体相互作用后,通过Src及Syk依赖的酪氨酸激酶途径活化下游分子,最终激活PLCγ2,产生第二信使的生理效应,引起血小板活化聚集。研究表明CLEC-2与配体的相互作用和血栓性疾病、肿瘤转移和进展以及血小板捕获HIV 1并呈递给靶细胞等过程密切相关。因此,阻断两者相互作用可能成为治疗上述疾病的新靶点。

The research progress of calcium-dependent lectin-like receptor 2 (CLEC-2)

Calcium dependent lectin like receptor 2 (CLEC-2) is a platelet surface receptor,which is a type II transmembrane receptor,and its relative molecular mass (Mr) is about 32 000.Venom protein Rhodocytin and sialic acid like glycoprotein Podoplanin were identified as exogenous and endogenous ligands of CLEC-2.The ligand receptor interacted through the Src and Syk dependent tyrosine kinase pathway to activate downstream molecules as well as PLCγ2,and result in excreting the physiological effects of second messengers,then causing the activation and aggregation of platelet.Recent evidence suggested that CLEC-2 was one of the key regulators of thrombotic diseases,tumor metastasis,and the procedure that HIV-1 captured by platelets and then handed to the target cells.Hence,blocking the interaction between CLEC-2 and its ligand was expected to be a new target in treating these diseases.